Evidence map›Paper›PMID 42155731›Full record

ArticleMolecular & cellular proteomics : MCP2026

Improved Peptide Search for Identification of SUMO and Sequence-Based Modifiers, in MaxSBM.

Caroline Lennartsson, Pelagia Kyriakidou, Michael Lund Nielsen, Jesper Velgaard Olsen, Jürgen Cox, Ivo Alexander Hendriks

Abstract read
In one paragraph

Article in Molecular & cellular proteomics : MCP, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Caroline LennartssonNovo Nordisk Foundation Center for Protein Research, Department of Cellular and Molecular Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Pelagia KyriakidouComputational Systems Biochemistry, Max-Planck Institute of Biochemistry, Martinsried, Germany.
Michael Lund NielsenNovo Nordisk Foundation Center for Protein Research, Department of Cellular and Molecular Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; Department of Molecular Biology and Genetics, Aarhus University, Aarhus, Denmark.
Jesper Velgaard OlsenNovo Nordisk Foundation Center for Protein Research, Department of Cellular and Molecular Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; Faculty of Health and Medical Sciences, Department of Cellular and Molecular Medicine, Copenhagen Center for Glycocalyx Research, University of Copenhagen, Copenhagen, Denmark.
Jürgen CoxComputational Systems Biochemistry, Max-Planck Institute of Biochemistry, Martinsried, Germany. Electronic address: cox@biochem.mpg.de.
Ivo Alexander HendriksNovo Nordisk Foundation Center for Protein Research, Department of Cellular and Molecular Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; Faculty of Health and Medical Sciences, Department of Cellular and Molecular Medicine, Copenhagen Center for Glycocalyx Research, University of Copenhagen, Copenhagen, Denmark. Electronic address: ivo.hendriks@cpr.ku.dk.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Post-translational modifications (PTMs), such as Small Ubiquitin-like Modifier (SUMO)ylation and ubiquitination, regulate key cellular processes by covalently attaching to lysine residues. While mass spectrometry allows site-specific identification of PTMs, most existing search engines are optimized for small, non-fragmenting modifications and struggle to detect large, fragmenting protein-based modifiers. We refer to these as sequence-based modifiers (SBMs). To overcome this limitation, we developed an SBM-specific search strategy within MaxQuant that accounts for the fragmentation behavior of SBMs during peptide identification. Using publicly available datasets, we validated our approach for SUMO2/3. Our analysis identified distinct diagnostic features and characteristic mass shifts associated with SBM fragmentation, referred to in this study as d-ions (diagnostic ions) and p-ions (PTM ions). By leveraging these features, our method improved the identification of SUMOylated peptides from human cell lines by ∼13%, SUMOylation sites in mouse embryonic cells by ∼22%, and in mouse adipocytes by ∼24%. Our search method improved spectral annotation of SBMs by up to 9% increase in the median Andromeda score. Taken together, we highlight the potential of our SBM search to enhance the discovery of protein-based modifications.

Indexed as

PeptidesProteomicsSmall Ubiquitin-Related Modifier ProteinsUbiquitinsAdipocytesAmino Acid SequenceAnimalsHumansMiceProtein Processing, Post-TranslationalSumoylationPeptidesSmall Ubiquitin-Related Modifier ProteinsSUMO2 protein, humanSUMO2 protein, mouseSUMO3 protein, humanSumo3 protein, mouseUbiquitinsdata dependent acquisitionendogenouslabel free quantificationmass spectrometrypeptide identificationproteomicsPTMsequence-based modifiersSUMOSUMOylationubiquitinubiquitination

Identifiers

PMID42155731
PMCPMC13292685

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.